M3 Biotechnology Completes Successful Funding Round

M3 Biotechnology Inc has completed an oversubscribed Series A-Round funding.
According to the press release:

the round was intended to be an $8 million raise but was expanded to $10 million because of strong investor interest in the company that could soon be at the leading edge of the emerging field of regenerative medicine with its drug that would regrow brain cells, reversing Alzheimer’s and Parkinson’s.

CEO Leen Kawas commented:

That strong interest was boosted not only by what she described as the “biggest investment,” by the Montgomery brothers, but also investments by W-Fund and WRF Capital, both important because of their commitments to invest in the most promising startups emerging from the state’s non-profit and research institutions.

Click here to view the full press release.